ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2017

Abstract Number: 451

A Matrix Risk Model for Prediction of Radiographic Progression in Early Rheumatoid Arthritis Based on Treatment Response at 3 Months

Pooneh S. Akhavan1, Daming Li1, Sahar Tabatabvakili1 and Edward C. Keystone2, 1Mount Sinai Hospital, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2017

Date of first publication: September 18, 2017

Keywords: joint damage, prognostic factors and rheumatoid arthritis, treatment

Session Information

Date: Sunday, November 5, 2017

Title: Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The present study aimed to develop a matix to predict risk of radiographic progression in patients with early rheumatoid arthritis. The focus of this analysis was to identify a threshold for routine disease activity measures at 3 months i.e. response to initial treatment that is associated with the lower risk of future joint damage.

Methods: Using data from the PREMIER study, radiographic progression (RP) was defined as a change in modified Sharp/van der Heijde score (SHS) of ≥3.5 U/year. Patients enrolled into the control arm of the study who received methotrexate only were analyzed. Baseline characteristics and disease activity measures at 3 months were used to predict the risk of RP at 12 months. Logistic regression was used to identify the predicators and to calculate the probability of RP. Significant predicators were categorized in order to make the models more practical to use in daily practice. The results were combined into a matrix model including significant predictors of RP.

Results:

A total of 205 patients were included in this analysis with a mean (sd) baseline age 52.0 (13.1) years, disease duration 0.8 (0.8) year, 28 swollen joint count 14.7 (5.7), 28 tender joint count 17.1 (6.4), mean sharp score (MTSS) 21.4 (21.2) and CRP 4.0 (4.1). Logistic regression models identified month 3 SJC and CRP as significant predicators of radiographic damage progression at 1 year. These variables were categorized into three groups based on the variable distribution and clinical relevance. The matrix model showed that the SJC < 5 at 3 months was associated with a significantly lower damage progression rate at any given CRP category (Table-1).

CRP at 3 months

SJC at 3 months

<1

1 – 2

>2

< 5

0.15 (0.08, 0.27)

0.36 (0.20, 0.57)

0.50 (0.29, 0.70)

5 – 10

0.30 (0.18, 0.46)

0.58 (0.35, 0.77)

0.70 (0.49, 0.85)

> 10

0.35 (0.22, 0.52)

0.63 (0.42, 0.81)

0.75 (0.57, 0.87)

Conclusion: The disease activity state at 3 months has a significant impact on future radiographic damage. Patients with less than 5 swollen joints at this time point have lower risk of radiographic damage at 1 year. Further testing in other populations and with different therapies is needed to obtain a definitive risk model that will guide rheumatologists in making treatment decisions for early RA patients.


Disclosure: P. S. Akhavan, None; D. Li, None; S. Tabatabvakili, None; E. C. Keystone, Abbott Laboratories, Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, F. Hoffmann-La Roche Inc, Janssen Inc, Lilly Pharmaceuticals, Novartis Pharmaceuticals, Pfizer Pharmaceuticals, Sanofi-Aventis, UCB, 2,Abbott Laboratories, AstraZeneca Pharma, Biotest, Bristol-Myers Squibb Company, Crescendo Bioscience, F. Hoffmann-La Roche Inc, Genentech Inc, Janssen Inc, Lilly Pharmaceuticals, Merck, Pfizer Pharmaceuticals, UCB, 5,Amgen, Abbott Laboratories, Astrazeneca LP, Bristol-Myers Squibb Canada,, 8.

To cite this abstract in AMA style:

S. Akhavan P, Li D, Tabatabvakili S, Keystone EC. A Matrix Risk Model for Prediction of Radiographic Progression in Early Rheumatoid Arthritis Based on Treatment Response at 3 Months [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/a-matrix-risk-model-for-prediction-of-radiographic-progression-in-early-rheumatoid-arthritis-based-on-treatment-response-at-3-months/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-matrix-risk-model-for-prediction-of-radiographic-progression-in-early-rheumatoid-arthritis-based-on-treatment-response-at-3-months/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology